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Abstract
Use of antiseptics and disinfectants is essential in infection control practices in hospital and other healthcare settings. In this study, the
in vitro activity of a new promising compound, para-guanidinoethylcalix[4]arene (Cx1), has been evaluated in comparison with hexami-
dine (HX) and chlorhexidine (CHX), two older cationic antiseptics. The MICs for 69 clinical isolates comprising methicillin-resistant
Staphylococcus aureus, methicillin-sensitive S. aureus, coagulase-negative staphylococci (CoNS) (with or without mecA), vancomycin-resis-
tant enterococci, Enterobacteriaceae producing various b-lactamases and non-fermenting bacilli (Pseudomonas aeruginosa, Acinetobacter bau-
manii, Stenotrophomonas maltophilia) were determined. Cx1 showed similar activity against S. aureus, CoNS and Enterococcus spp.,
irrespective of the presence of mecA or van genes, or associated resistance genes, with very good activity against CoNS (MIC <1 mg/L).
Variable activities were observed against Enterobacteriaceae; the MICs determined seemed to be dependent both on the genus (MICs of
2, 8 and 64 mg/L for Escherichia coli, Klebsiella pneumoniae and Yersinia enterocolitica, respectively) and on the resistance phenotype pro-
duction of [Extended Spectrum b-Lactase (ESBLs) or other b-lactamases; overproduction of AmpC]. Poor activity was found against
non-fermenting bacilli, irrespective of the resistance phenotype. CHX appeared to be the most active compound against all strains, with
broad-spectrum and conserved activity against multidrug-resistant strains. HX showed a lower activity, essentially against Gram-positive
strains. Consequently, the differences observed with respect to Cx1 suggest that they are certainly not the consequence of antibiotic
resistance phenotypes, but rather the result of membrane composition modifications (e.g. of lipopolysaccharide), or of the presence of
(activated) efflux-pumps. These results raise the possibility that Cx1 may be a potent new antibacterial agent of somewhat lower activity
but significantly lower toxicity than CHX.
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Introduction
Quaternary ammonium compounds (QAC) such as benzalko-
nium chloride, bisbiguanides such as chlorhexidine (CHX),
polymeric biguanides such as polyhexamethylene biguanide
(PHMB) and diamidines such as hexamidine (HX) have been
widely used for over half a century [1]. Due to their intrinsic
positive charge, these cationic compounds bind with high
affinity to the negatively charged cell walls and membranes of
bacteria, and disruption is brought about by perturbations of
the binding sites [2]. Biocides are clearly different from anti-
biotics with respect to their (i) mode of action, (ii) condition
of use, and (iii) acquired and intrinsic mechanisms by which
bacteria resist their effects. However, intensive exposure of
hospital pathogens to biocides, similar to that of antibiotics,
may result in the emergence of—often associated—resis-
tance to these agents [3]. For example, qac genes (which
confer resistance to quaternary ammonium compounds) are
often found in Staphylococcus aureus strains carrying mecA
genes or the b-lactamase gene blaZ, on transposon Tn552
[4,5]. The progressive reduction of the therapeutic effective-
ness of the available antibiotics and antiseptics as a result of
the spread of antimicrobial resistance underlines (i) the
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necessity to evaluate the efficiency of available antiseptics,
and (ii) the urgency of the development of new classes of
drugs for the treatment of infectious diseases. A major
challenge is to find drugs that act against multiple multidrug-
resistant strains.
The antimicrobial activity of a new antibacterial drug,
para-guanidinoethylcalix[4]arene (Cx1), has been tested and
is presented here. This lead compound is a novel member of
the family of cationic antibacterial compounds; it is a calixa-
rene-based compound with four guanidinium functions, which
may interact with the negatively charged bacterial cell wall.
Cx1 shows high water solubility, with broad in vitro activity
against Gram-positive and Gram-negative bacteria [6]. More-
over, it is devoid of cytotoxicity against two eukaryotic cell
lines, HaCaT and MRC-5. By contrast HX and CHX show
effects on cell viability after only 24 h exposure [6; M. Grare
and R. E. Duval, unpublished data].
The purpose of this study was: (i) to extend knowledge
about the in vitro activities of two widely used antiseptics,
HX and CHX, by testing them against 39 multidrug-resistant
Gram-positive bacteria [15 S. aureus, methicillin-resistant
S. aureus (MRSA) or methicillin-sensitive S. aureus (MSSA),
12 coagulase-negative staphylococci (CoNS), resistant or
susceptible to methicillin, 14 Enterococcus spp., with or
without van genes] and 30 multidrug-resistant Gram-
negative bacteria (20 Enterobacteriaceae, with or without
ESBL, and ten non-fermenting bacilli); and (ii) to investigate
the potential of a new antibacterial drug, named Cx1, against
these pathogens.
Materials and Methods
Bacterial strains
Escherichia coli ATCC 25922, S. aureus ATCC 25923 and
ATCC 29213, E. faecalis ATCC 29212 and Pseudomonas aeru-
ginosa ATCC 27853 were used as reference strains following
guidelines of the CLSI (formerly NCCLS) [7] and of the
Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise de
Microbiologie [8]. Other reference strains were chosen to
represent susceptible strains corresponding to resistant clini-
cal isolates tested: Proteus mirabilis ATCC 43071, Klebsiella
oxytoca ATCC 700324, Providencia stuartii ATCC 33672,
Yersinia enterocolitica ATCC 9610, Acinetobacter baumanii
ATCC 19606, S. epidermidis ATCC 12228 and Streptococcus
pneumoniae ATCC 49619. Also included were two VISA
strains (Mu3 and Mu50) [9].
Sixty-nine clinical isolates were collected from University
Hospital of Nancy: (i) 39 multidrug-resistant Gram-positive
isolates including three MSSA, ten MRSA, 12 CoNS resistant
(n = 10) or not resistant (n = 2) to methicillin and 14
Enterococcus spp., with or without van genes; (ii) 30
multidrug-resistant Gram-negative isolates including 20 ESBL-
producing or -non-producing isolates of Enterobacteriaceae
and 10 non-fermenting bacilli.
Each isolate was from a different patient, and each was
judged to be clinically significant when it was first recovered.
Isolates were selected on the basis of their antimicrobial sus-
ceptibility profile. Antimicrobial resistances were determined
by the automated instrument VITEK2 (bioMerieux, Marcy
L’Etoile, France). The presence of resistance genes was inves-
tigated by PCR multiplex analysis adapted from methods pre-
viously described by Dutka-Malen et al. [10] for van genes,
or Del Vecchio et al. [11] for mecA genes. Strains were
grown on Mueller Hinton agar (BD, 225250) or in Mueller
Hinton broth (MHB) (BD, 275730), complemented with 5%
lysed sheep blood for the streptococci.
Antimicrobial agents
Three drugs were tested: hexamidine diisethionate
(FW = 668.22; compound 1), chlorhexidine digluconate
(FW = 897.74; compound 2), and para-guanidinoethylca-
lix[4]arene (FW = 1221.1; compound 3) (Fig.1.)
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FIG. 1. Chemical structure of: (1) hexamidine diisethionate (HX);
(2) chlorhexidine digluconate (CHX); and (3) para-guanidinoethylca-
lix[4]arene (Cx1).
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Compound 3 was prepared as trifluoroacetate salts as
described previously [12]. Compounds 1 and 2 were
obtained by evaporation and freeze-drying in commercial
alcoholic solution at 1& (w/vol). The three compounds were
fully characterized, and each batch was controlled by means
of 1H and 13C NMR elemental analyses. Solutions were
freshly prepared at the beginning of each week and kept at
4C. The solutions were filtered through a 0.22 lm-
pore-size filter (Millex GP; 0.22 lm, Millipore, Saint Quentin
en Yvelines, France) before each experiment.
MIC determination
MICs were determined using the broth microdilution
method recommended by the CLSI [7], and as described
previously [6]. For microdilution susceptibility testing of ref-
erence strains, assays were made in Mueller-Hinton media
supplemented or not with magnesium (12.5 mg/L) and cal-
cium (25 mg/L) in order to evaluate the influence of cations
on MICs. Results are expressed as means of four indepen-
dent determinations.
Results
The MICs of all compounds are provided in Tables 1–3. The
presence of magnesium (12.5 mg/L) and calcium (25 mg/L)
did not appear to affect the MICs, compared with those
determined in unsupplemented MHB (data not shown).
For the two S. aureus reference strains (ATCC 25923 and
ATCC 29213) and for three mecA-negative strains, the MIC
of Cx1 was 4–8 mg/L (Table 1). No difference in activity was
seen for ten mecA-positive strains or for the two VISA
strains (Mu3 and Mu50) (MIC 4–8 mg/L for all strains). Cx1
showed better activity against CoNS (S. epidermidis, S. hominis,
S. warneri), independent of the resistance phenotype (MIC
<1 mg/L for almost all strains, two mecA-negative and ten
mecA-positive) (Table 1). HX showed more variable and
moderate activity (MIC range <1–32 mg/L), with reduced
activity against the VISA strains tested (MIC = 128–256
mg/L). CHX was the most active compound against staphylo-
cocci (MIC <1 mg/L for all strains).
Three E. faecalis strains (two vanA-positive), eight E.
faecium strains (six vanA-positive and two vanB-positive) and
one strain each of E. avium (vanB), E. gallinarum and E. casseli-
flavus were tested for susceptibility to Cx1, HX and CHX.
Cx1 was more active against E. faecium strains, whatever the
resistance phenotype (MIC range 8–16 mg/L for E. faecium,
vs. 32–64 mg/L for E. faecalis strains) (Table 1).
Both the species and the Van phenotype seemed to influ-
ence Cx1 efficacy with MICs of 8–64 mg/L for vanA+ strains,
4–16 mg/L for vanB+ strains (4 mg/L for E. avium), and of 2
and 16 mg/L, respectively, for strains of E. gallinarum (vanC1+)
and E. casseliflavus (vanC2/C3+), both naturally non-susceptible
to glycopeptides (Table 1). CHX and HX displayed very
good activity against vancomycin-resistant enterococci (VRE),
irrespective of species or resistance phenotype (MIC range
<1–2 mg/L of CHX, and 4–16 mg/L of HX) (Table 1).
TABLE 1. In vitro activities of para-guanidinoethyl-
calix[4]arene (Cx1), hexamidine (HX) and chlorhexidine
(CHX) against Staphylococcus aureus, coagulase-negative
staphylococci (CoNS), and Enterococcus spp., with various
resistance phenotypes. (): number of strains tested
Strains Tested agents MIC (mg/L)
S. aureus ATCC 25923 Cx1 8
HX 2
CHX <2
S. aureus ATCC 29213 Cx1 8
HX <1
CHX <1
MSSA (3) Cx1 4–8
HX <1
CHX <1
MRSA (10) Cx1 4–8
HX <1–32
CHX <1
VISA (Mu3) Cx1 18
HX 256
CHX <1
VISA (Mu50) Cx1 8
HX 128
CHX <1
S. epidermidis ATCC 12228 Cx1 <1
HX <1
CHX <1
MS-CoNS (2) Cx1 <1
HX <1
CHX <1
MR-CoNS (10) Cx1 <1–2
HX <1–8
CHX <1
E. faecalis ATCC 29212 Cx1 32
HX 2
CHX <1
E. faecalis Cx1 64
HX 4
CHX <1
E. faecalis van A (2) Cx1 64
HX 4
CHX <1–2
E. faecium van A (6) Cx1 8–16
HX 4
CHX <1–2
E. faecium van B (2) Cx1 Cx1
HX 4
CHX 8–16
E. avium van B Cx1 4
HX 8
CHX 1
E. gallinarum (van C1) Cx1 16
HX 4
CHX 2
E. casseliflavus (van C2/C3) Cx1 2
HX 16
CHX 2
S. pneumoniae ATCC 49619 Cx1 16–32
HX <1
CHX <1
MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; MS,
methicillin-sensitive; MR, methicillin-resistant; VISA, vancomycin-intermediate
S. aureus.
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Concerning antimicrobial activity against Enterobacteriaceae,
more marked variations were observed whatever the
compounds tested. As for Cx1, good activity was noted
against E. coli, with particularly good efficiency against
ESBL-producing clinical isolates (MICs 2–4 mg/L for all E. coli
strains) (Table 2). Good activity was also observed against
K. oxytoca ATCC 700324, K. pneumoniae, Citrobacter koseri
and Morganella morganii (MICs = 16, 8, 4 and 8 mg/L, respec-
tively) (Table 2). As for resistant clinical isolates, a significant
decrease in activity was observed with an 8–32-fold MIC
increase (MIC = 8–64 mg/L for ESBL-producing K. pneumoniae
and >256 mg/L for AmpC-overproducing Morganella morga-
nii). As for Enterobacter cloacae, surprisingly only minimal
activity of the compound was observed against the wild-type
strain and against the AmpC-hyperproducing strain
(MIC = 256 mg/L). However, greater activity was observed
when the strain expressed an ESBL (MIC = 32 mg/L). Some
Enterobacteriaceae showed a natural lack of susceptibility to
Cx1.
Those tested were: Proteus mirabilis, Proteus vulgaris, Provi-
dencia stuartii, Serratia marcescens and Yersinia enterocolitica
(for these species, MICs were between 64 and >256 mg/L)
(Table 2). Similar observations were made for HX, generally
showing poor activity against Enterobacteriaceae (MIC
‡64 mg/L for almost all strains tested) (Table 2). Once again,
CHX seemed to be the more active compound with very
low MICs [<1 mg/L (for E. coli, including ESBL-
producing strains) to 32 mg/L (for AmpC-overproducing
M. morganii and S. marcescens)] (Table 2).
To all compounds evaluated in this study, non-fermenting
bacilli were the least susceptible. The MICs of Cx1 ranged
from 32 to >256 mg/L (the more resistant strains were
TABLE 2. In vitro activities of para-guanidinoethylcalix[4]-
arene (Cx1), hexamidine (HX) and chlorhexidine (CHX)
against Enterobacteriaceae, with various resistance
phenotypes. (): number of strains tested
Strains
Tested
agents
MIC
(mg/L)
Escherichia coli ATCC 25922 Cx1 4
HX 8
CHX <1
Penicillinase-producing E. coli Cx1 2
HX 8
CHX <1
AmpC-hyperproducing E. coli Cx1 2
HX 16
CHX <1
ESBL-producing E. coli (4) Cx1 2
HX 16–64
CHX <1–2
Proteus mirabilis ATCC 43071 Cx1 256
HX 256
CHX 16
Penicillinase-producing P. mirabilis Cx1 256
HX 64
CHX 2
Proteus vulgaris Cx1 64
HX 16
CHX 8
Klebsiella oxytoca ATCC 700324 Cx1 16
HX 16
CHX 4
K. pneumoniae Cx1 8
HX 64
CHX 4
ESBL-producing K. pneumoniae (2) Cx1 8–64
HX 32–64
CHX 2–4
Citrobacter koseri Cx1 4
HX 16
CHX < 1
Providencia stuartii ATCC 33672 Cx1 64
HX 64
CHX 4
Fluoroquinolones-resistant P. stuartii Cx1 256
HX 16
CHX <1
Enterobacter cloacae Cx1 256
HX >256
CHX 8
AmpC-hyperproducing E. cloacae Cx1 >256
HX 128
CHX 8
ESBL-producing E. cloacae Cx1 32
HX 256
CHX 4
Morganella morganii Cx1 8
HX 64
CHX 8
AmpC-hyperproducing Morganella morganii Cx1 >256
HX 32
CHX 32
Serratia marcescens Cx1 >256
HX 256
CHX 32
Yersinia enterocolitica ATCC 9610 Cx1 16
HX 32
CHX 4
Y. enterocolitica Cx1 64
HX 16
CHX 8
TABLE 3. In vitro activities of para-guanidinoethylcalix[4]-
arene (Cx1) and comparators against non-fermenting
bacilli, with various resistance phenotypes. (): number of
strains tested
Strains
Tested
agents
MIC
(mg/L)
Pseudomonas aeruginosa ATCC 27853 Cx1 32
HX 32
CHX 4
Fluoroquinolones-resistant P. aeruginosa Cx1 32
HX 32
CHX 8
Porine D2-modified P. aeruginosa Cx1 64
HX 64
CHX 4
Multidrug-resistant P. aeruginosa (3) Cx1 64–256
HX 32–64
CHX 4–16
Acinetobacter baumanii ATCC 19606 Cx1 256
HX 32
CHX 8
Multidrug-resistant A. baumanii (2) Cx1 128–256
HX 32–64
CHX 4–16
Burkholderia cepacia Cx1 18
HX <1
CHX <1
Multidrug-resistant Stenotrophomonas maltophilia (2) Cx1 256
HX 32–256
CHX <1–32
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Stenotrophomonas maltophilia and A. baumanii) and the MICs
of HX ranged from <1 to 32 mg/L (Table 3). Burkholderia
cepacia seemed to be the more susceptible strain, whichever
the compound tested (MICs of Cx1, HX and CHX = 8, <1
and <1 mg/L, respectively (Table 3).
Discussion
The discovery and application of antimicrobial chemotherapy
and the use of biocides in the form of antiseptics and disin-
fectants, particularly in the latter half of the 20th century,
has allowed control over most infectious diseases. Cationic
antibacterials such as CHX and QACs have been shown to
be helpful in reducing the spread of multidrug-resistant
strains and hospital-acquired infections [13]. CHX is a known
antiseptic, active against a wide range of Gram-positive and
Gram-negative bacteria, but few data are available about its
activity against resistant clinical isolates. MIC values of CHX
determined in this study were comparable to those obtained
by other authors [14–16]. It was demonstrated under
laboratory conditions that this antiseptic is active against var-
ious strains of MRSA, MR-CoNS, VRE and antibiotic-resistant
Enterobacteriaceae. Concerning the activity of CHX against
Enterobacteriaceae and non-fermenting bacilli, it is noticed
that this antibacterial activity (i.e. of CHX) is more heteroge-
neous (or variable) according to genus and phenotype resis-
tance, as previously described [15]. However, a higher
in vitro cytotoxicity of this antiseptic was observed in expo-
sures of up to 24 h (M. Grare and R. E. Duval, unpublished
data). Moreover, other authors have demonstrated that
CHX is highly cytotoxic in vitro (for osteoblastic, endothelial
and fibroblastic cell lines) [17]. As for HX, this study con-
firms reduced activity compared with CHX, with the spec-
trum reduced to Gram-positive bacteria. Activity was
observed against MRSA and VRE; this could be of interest in
controlling the spread of these pathogens. However, HX and
CHX also present high cytotoxicity during exposures of up
to 24 h, in addition to reduced spectrum of activity [6].
These cumulative data provide supplementary arguments to
investigate and research new compounds, with a comparable
broad spectrum but lower cytotoxicity, and prompted the
current investigation into a new cationic compound, Cx1,
against multidrug-resistant clinical isolates. Cx1 seemed to be
a very interesting and potent antibacterial, with an extended
spectrum, one larger than that of HX, but slightly narrower
than that of CHX. Activity was observed against MRSA,
MR-CoNS, VRE and ESBL-producing Enterobacteriaceae; more
remarkably, we have previously demonstrated that Cx1 is
devoid of cytotoxicity in vitro [6]. Compared with HX and
CHX, which are highly cytotoxic cationic antiseptics, the low
cytotoxicity of Cx1 makes it a very promising new antibacte-
rial agent.
Relating the data of Cx1 activity against clinical isolates to
its mechanism of action, there appears to be no correlation
between resistance to antibiotics (particularly multidrug resis-
tance) and Cx1 efficacy. This implies that the mechanism of
action of Cx1 is independent of the antibiotic resistance phe-
notypes of the strains and isolates tested in this study. It is
considered unlikely that b-lactamase production or a PBP-
modification could influence the activity of Cx1, a synthetic
compound with a structure very different from that of b-lac-
tams. Considering its chemical structure (Fig. 1(3)), one
potential hypothesis for its mechanism of action is that the
four guanidium functions interact with the negative charges of
some specific components of the bacterial cell wall. This is
suggested by the variation in activity observed between
strains of the same genus or of the same species. Variations
in MICs were more noticeable with Gram-negative strains,
and the most striking variation was observed with Enterobac-
teriaceae. One of the characteristics of Gram-negative bacte-
ria is the presence of the outer membrane (OM). This
membrane is likely to be the first structure with which Cx1
interacts, and it is well known that the composition of the
OM, and particularly of lipopolysaccharide (LPS), is highly var-
iable among genera and species, even from one strain to
another. The observed differences between clinical isolates
suggest one or more physico-chemical interactions of Cx1
with the membrane. These interactions must depend on the
membrane composition, in particular the nature of the LPS,
and membrane properties, such as charge density and mem-
brane potential. Such differences in membrane composition
and properties could explain differences in the MICs
observed in this study for the various strains of Enterobacteria-
ceae. Considering the Gram-negative non-fermenting bacilli, it
may be worth noting that MICs are increased for clinical iso-
lates with active efflux-pumps relative to the reference strains
(as in the case of P. aeruginosa). The questions as to how Cx1
penetrates the OM, and how this compound can be extruded
by efflux systems, warrant further investigations into the
structure of the bacterial cell wall.
Finally, it is considered unlikely that b-lactamases, or
other enzymes that have specific affinity for antibiotics,
have any influence on the activity of Cx1. It may be more
pertinent to address the resistance of Enterococcus spp. to
glycopeptides, since this type of resistance implies a modifi-
cation in the composition of the pentapeptide precursor of
the peptidoglycan (lactate or serine, instead of alanine). The
change could imply modification of peptidoglycan organiza-
tion and of the degree of reticulation.
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Such modifications could potentially lead to altered inter-
actions with Cx1. It does not seem to be the case here: tak-
ing into account the ‘‘species’’, the van resistance phenotype
does not modify the MICs. However, ‘‘minor’’ modifications
in the composition of the peptidoglycan could perhaps
explain the differences observed, in terms of Cx1 activity,
against E. faecium and E. faecalis. When the composition of
the peptidoglycan is looked at, the disaccharide chains
(GlcNAc-MurNAc) and the pentapeptide are generally well
preserved within a same bacterial genus [18]. Indeed, if
Enterococcus spp. is considered, the peptidoglycan is mainly
constituted by a rich lysine-aspartate murein, with the excep-
tion of E. faecalis, species for which there is a majority of
lysine-alanine chains [19]; and it is noteworthy that E. faecalis
is the species for which the MICs of Cx1 are the highest.
This discrepancy probably results in a modification at the
level of (i) surface charge density and (ii) peptidoglycan orga-
nization and then, considering the hypothesis for the
mechanism of action of Cx1, in a difference in terms of bac-
terial sensibility to the cationic compound.
In conclusion, it has been demonstrated that (i) the antibi-
otic-resistant pathogens tested here have patterns of ele-
vated susceptibility to HX or CHX, and (ii) Cx1 can present
a good alternative to these two older antiseptics, which are
characterized by higher cytotoxicity. Also, in line with previ-
ous observations [20], it is suggested that the bacterial cell
wall is a potential target of Cx1. However, more detailed
studies are necessary to understand the mechanism(s) of
action of Cx1; these should include the analysis of structure/
activity relationships, of synergy with antibiotics, and of pep-
tidoglycan modification(s) in the presence of Cx1. So far, the
results presented here support the hypothesis that Cx1
could represent a novel cationic compound that, in the
opinion of the authors, may be valuable as an adjuvant for
antimicrobial chemotherapy or disinfection.
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